Trials / Recruiting
RecruitingNCT07369024
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults: A Randomized Control Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Mohsen Saidinejad · Academic / Other
- Sex
- All
- Age
- 5 Years – 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
Conditions
- Sickle Cell Disease
- Vaso-Occlusive Pain Episode in Sickle Cell Disease
- Ketamine Infusion
- Pain Management
- Vaso-Occlusive Crises
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sub-dissociative Ketamine Infusion | 0.25 mg/kg of IV ketamine within a 20-minute infusion of 100 milliliters of normal saline (NS) |
| DRUG | Normal Saline Placebo Infusion | 20-minute infusion of 100 milliliters of normal saline |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2027-12-31
- Completion
- 2028-04-30
- First posted
- 2026-01-27
- Last updated
- 2026-03-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07369024. Inclusion in this directory is not an endorsement.